Thus, our data and prior studies suggest that clinicians should not withhold potent P2Y12 inhibitors from overweight or obese MI patients out of efficacy concerns; these patients remain excellent candidates for intensive antiplatelet therapy, provided their bleeding risk is acceptable. Here, P2RY12 is linked to myocardial infarction.